



NEWS RELEASE

For Immediate Release

Contact:

BioWa, Inc.

Masamichi Koike, Ph.D
President and CEO
Phone: +1-609-734-3420

Martina Molsbergen
Vice President, Business Management
Phone: +1-609-734-3430

**BIOWA ANNOUNCES LICENSING OF
BIOWA'S POTELLIGENT[®] TECHNOLOGY BY GLAXOSMITHKLINE
FOR USE
IN ANTIBODY RESEARCH AND DEVELOPMENT**

Princeton, NJ, USA, October 19, 2007 – BioWa, Inc. (BioWa) announced today that it has entered into a research agreement which provides GlaxoSmithKline (GSK) with access to BioWa's patented POTELLIGENT[®] Technology platform for the development of antibody-dependent cellular cytotoxicity (ADCC) enhanced antibodies.

The agreement grants GSK non-exclusive rights to research and develop antibodies based on POTELLIGENT[®] Technology for an undisclosed number of targets. In return, BioWa will receive an upfront payment, and license fees. Other details of the agreement were not disclosed.

"GSK is an acknowledged leader in all aspects of pharmaceutical research and development," said Dr. Masamichi Koike, President and CEO of BioWa. "Given the breadth and depth of GSK's biopharmaceutical R&D capabilities, we are delighted to announce this collaboration which will help fulfill BioWa's mission to deliver the benefits of POTELLIGENT[®] Technology to patients as quickly as possible."

About POTELLIGENT[®] Technology

POTELLIGENT[®] Technology improves potency and efficacy of antibody therapeutics, by enhancing antibody-dependent cellular cytotoxicity (ADCC), one of the major mechanisms of antibody therapeutics. POTELLIGENT[®] Technology involves the reduction of the amount of fucose in the carbohydrate structure of an antibody using a proprietary fucosyltransferase-knockout CHO cell line as a production cell. Research shows that POTELLIGENT[®] Technology significantly enhances ADCC activity of an antibody *in vitro*, thereby increasing the potential for improved activity *in vivo*.

About BioWa, Inc.

BioWa is a wholly owned subsidiary of Kyowa Hakko Kogyo Co., Ltd., a major Japanese pharmaceutical and biotech company, and is the exclusive worldwide licensor of POTELLIGENT[®] Technology, which creates high ADCC monoclonal antibodies. Currently, BioWa is developing ADCC enhanced monoclonal antibody-based therapeutics to fight cancer and other life-threatening and debilitating diseases and both BioWa and Kyowa have POTELLIGENT[®] antibody products in various stages of clinical development. BioWa creates and develops enhanced ADCC antibodies for itself and for partners, offering a full range of antibody discovery and development capabilities. For more information about BioWa, visit its web site at www.biowa.com.

POTELLIGENT[®] is the trademark of Kyowa Hakko Kogyo Co., Ltd. All rights are reserved.

###